Short Interest in Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Expands By 28.9%

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) saw a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 10,430,000 shares, a growth of 28.9% from the March 31st total of 8,090,000 shares. Approximately 2.2% of the shares of the stock are sold short. Based on an average trading volume of 4,090,000 shares, the short-interest ratio is presently 2.6 days.

Analyst Ratings Changes

A number of analysts have recently issued reports on CATX shares. Oppenheimer restated an "outperform" rating and issued a $1.50 target price (up previously from $1.20) on shares of Perspective Therapeutics in a report on Monday, April 1st. B. Riley upped their price target on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the stock a "buy" rating in a research note on Tuesday, April 9th.

Insider Activity

In related news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business's stock in a transaction dated Wednesday, March 6th. The stock was bought at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the transaction, the insider now owns 116,773,394 shares of the company's stock, valued at 110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 5.72% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Perkins Capital Management Inc. acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at approximately $731,000. HighTower Advisors LLC acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at approximately $314,000. Bank of New York Mellon Corp acquired a new stake in shares of Perspective Therapeutics in the third quarter valued at approximately $42,000. Taylor & Morgan Wealth Management LLC lifted its position in shares of Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company's stock valued at $251,000 after buying an additional 50,000 shares during the last quarter. Finally, Simplicity Wealth LLC acquired a new stake in shares of Perspective Therapeutics in the first quarter valued at approximately $40,000. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Stock Down 1.3 %

CATX stock traded down 0.02 during mid-day trading on Friday, reaching 1.58. 4,686,100 shares of the stock traded hands, compared to its average volume of 6,322,404. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.07 and a quick ratio of 1.07. The stock has a market capitalization of $927.33 million, a price-to-earnings ratio of -15.80 and a beta of 1.56. Perspective Therapeutics has a 52 week low of 0.21 and a 52 week high of 1.77.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.